ArticlePloS one2025
Effects of essential tremor on longevity and mortality rates in families.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tremor pathophysiology.Clinical parkinsonism & related disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Essential Tremor (ET) is a common movement disorder characterized by action tremors, primarily affecting the hands and head. lthough previous studies have suggested potential links between ET and aging-related diseases, its relationship with longevity remains unclear, with conflicting evidence in the literature. To investigate this association, we analyzed data from 1,493 individuals across 145 families, encompassing both ET-positive (ET+) and ET-negative (ET-) participants. Using comprehensive statistical methods, including survival function estimation and regression modeling, we examined the potential influence of ET on lifespan. The median age of our participants was 67 years (IQR 54-77). Among deceased individuals, those with ET had a higher median age at death (80 years, IQR 70-86) compared to their ET- counterparts (70 years, IQR 59-77). Living ET+ participants also demonstrated slightly higher median ages (63 years, IQR 53-74) than living ET- individuals (60 years, IQR 49-71). Survival analysis revealed a significantly prolonged lifespan for ET+ individuals compared to ET- individuals (log-rank p = 1.11 × 10 ⁻23). Furthermore, hazard ratio (HR) calculations indicated a reduced risk of mortality for the ET+ group (HR = 0.44, CI95% = 0.37-0.52), particularly among males. These findings suggest that ET may be associated with increased longevity, though the underlying biological mechanisms remain unclear. Further research is essential to elucidate the processes contributing to this relationship and to explore its implications for understanding aging and neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.